Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters

Drug‐drug interaction (DDI) is an important consideration for clinical decision making in prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, an oral androgen receptor inhibitor, on the pharmacokinetics (PK) of digoxin (P‐glycoprotein [P‐gp] probe subst...

Descripción completa

Detalles Bibliográficos
Autores principales: Poondru, Srinivasu, Ghicavii, Vitalii, Khosravan, Reza, Manchandani, Pooja, Heo, Nakyo, Moy, Selina, Wojtkowski, Tomasz, Patton, Melanie, Haas, Gabriel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099123/
https://www.ncbi.nlm.nih.gov/pubmed/35118821
http://dx.doi.org/10.1111/cts.13229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099123/
https://www.ncbi.nlm.nih.gov/pubmed/35118821
http://dx.doi.org/10.1111/cts.13229

Ejemplares similares